Chinese Abraham Investment Advisors

Abraham Ceesay, the founder and managing partner, runs all investment decisions. Ceesay built his wealth through pharmaceutical distribution across Sierra Leone and West Africa before formalizing the family office in 2015. No other investment committee members or partners have been publicly identified.

The firm is not an operating company but the private investment vehicle for Abraham Ceesay, whose wealth derived from African pharmaceutical distribution ventures. The office invests in digital health and healthcare services companies, drawing on Ceesay's sectoral expertise, but maintains no disclosed ownership stake in any operating pharmaceutical distributor.

No. While the firm publicly articulated an Afrocentric thesis in 2022 — targeting startups that serve or are led by the African diaspora — its portfolio also includes US-based digital health and enterprise software companies without an explicit Africa connection. The office maintains a dual focus: early-stage US ventures and selected West African tech opportunities, particularly in Nigeria and Ghana.

The office concentrates on seed and Series A rounds, with check sizes typically ranging from $250,000 to $2 million. It occasionally participates in follow-on financing through special purpose vehicles. No later-stage growth equity or buyout activity has been publicly documented.

Chinese Abraham operates as a single family office managing the capital of Abraham Ceesay exclusively. The firm does not accept outside limited partners, nor has it disclosed any multi-family office conversion or wealth-management offering for other families.